BOCA RATON, Fla.–(BUSINESS WIRE)–Die Cataltheia Group und ihre US-Tochtergesellschaft Bruno Vision Care LLC, ein führendes Unternehmen im Bereich der Augenheilkunde, gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Dru…
Category: Business
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia
BOCA RATON, Fla.–(BUSINESS WIRE)–The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable …
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today responded to the fourth po…
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR t…
Ollin Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced that Jason Ehrlich, M.D., Ph.D….
Bausch + Lomb Announces Two Board of Directors Appointments
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appoin…
Future Forward Labs Appoints Dr. Delia DeBuc as Applied Science Mentor to Advance Applied Physics and Biomedical Innovation
SEATTLE–(BUSINESS WIRE)– #highschool–Future Forward Labs today announced the appointment of Dr. Delia DeBuc as STEM Mentor – Applied Physics and Biomedical Science. Dr. DeBuc brings more than 20 years of multidisciplinary research, scientific leader…
Dompé verabreicht Isocyclosporin an erste Patienten einer Phase-3-Studie in Europa und den USA für die Indikation atopische Keratokonjunktivitis
MAILAND und SAN MATEO, Kalifornien, USA–(BUSINESS WIRE)–Dompé, ein führendes Biopharmaunternehmen mit Niederlassungen in Italien und den USA, meldete die Aufnahme der ersten Patienten in eine Phase-3-Studie zu Isocyclosporin für die Behandlung von at…
Dompé behandelt eerste patiënten in Europa en de VS in fase 3-onderzoek naar isocyclosporine voor atopische keratoconjunctivitis
MILAAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, een toonaangevend biofarmaceutisch bedrijf met activiteiten in Italië en de VS, heeft aangekondigd dat de eerste patiënten zijn ingeschreven voor een fase 3-onderzoek naar isocyclosporine voor de beha…
Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today re…
Dompé somministra le dosi ai primi pazienti in Europa e negli Stati Uniti nello studio di fase 3 sull'isociclosporina per la cheratocongiuntivite atopica
MILANO e SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato l’arruolamento dei primi pazienti in uno studio di fase 3 sulla isociclosporina per il trattament…
Dompé somministra le dosi ai primi pazienti in Europa e negli Stati Uniti nello studio di fase 3 sull'isociclosporina per la cheratocongiuntivite atopica
MILANO e SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato l’arruolamento dei primi pazienti in uno studio di fase 3 sulla isociclosporina per il trattament…
Dompé administre les premières doses à des patients en Europe et aux États-Unis dans le cadre d'une étude de Phase 3 sur l'isocyclosporine pour traiter la kératoconjonctivite atopique
MILAN et SAN MATEO, Californie–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, annonce que les premiers patients ont été admis dans une étude de Phase 3 sur l’isociclosporine sur le traiteme…
Dompé administre les premières doses à des patients en Europe et aux États-Unis dans le cadre d'une étude de Phase 3 sur l'isocyclosporine pour traiter la kératoconjonctivite atopique
MILAN et SAN MATEO, Californie–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, annonce que les premiers patients ont été admis dans une étude de Phase 3 sur l’isociclosporine sur le traiteme…
Dompé inicia en Europa y Estados Unidos un estudio de fase 3 de isociclosporina en pacientes con queratoconjuntivitis atópica
MILÁN y SAN MATEO, California–(BUSINESS WIRE)–Dompé, empresa biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado el inicio de la inclusión de los primeros pacientes en un estudio de fase 3 de isociclosporina para el tratami…
Dompé inicia en Europa y Estados Unidos un estudio de fase 3 de isociclosporina en pacientes con queratoconjuntivitis atópica
MILÁN y SAN MATEO, California–(BUSINESS WIRE)–Dompé, empresa biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado el inicio de la inclusión de los primeros pacientes en un estudio de fase 3 de isociclosporina para el tratami…
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported that independent industry analysts have r…
Tenpoint Therapeutics, Ltd. to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that Henric Bjarke, Chief Executive …
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food an…